Journal article icon

Journal article

A trial of Itraconazole or Amphotericin B HIV-associated talaromycosis

Abstract:

Background

Talaromyces marneffei infection is a major cause of HIV-related death in South and Southeast Asia. Guidelines recommend initial treatment with amphotericin B deoxycholate but it has significant side effects, high cost and limited availability. Itraconazole is orally available, better- tolerated and widely-used in place of amphotericin; however, these two strategies have not been compared in clinical trials.

Methods

In this open-label non-inferiority trial, we randomly assigned 440 HIV-infected adults with microscopy- or culture-confirmed talaromycosis between October 2012 and December 2015 across Vietnam to receive amphotericin 0.7 mg/kg/day (N=219) or itraconazole 400 mg/kg/day (N=221) for two weeks, followed by itraconazole maintenance therapy in all patients. The primary outcome was mortality by two weeks. Secondary outcomes included mortality by week 24, time to clinical resolution, early fungicidal activity, disease relapse, immune reconstitution inflammatory syndrome (IRIS), and tolerability.

Results

Mortality by two weeks was 6.5% in the amphotericin group and 7.4% in the itraconazole group (absolute risk difference, 0.9 percentage points; 95% confidence interval [CI], -3.9 to 5.7 percentage points; non-inferiority P<0.0001); however, mortality risks by week 24 were 11.3% and 21.0%, respectively (absolute risk difference, 9.7 percentage points; 95% CI, 2.8 to 16.6 percentage points; P=0.006). Amphotericin was associated with significantly faster clinical resolution and fungal clearance, and lower rates of relapse and immune reconstitution inflammatory syndrome (IRIS). Patients on amphotericin experienced more infusion reactions, renal failure, hypokalemia, hypomagnesaemia, and anemia.

Conclusions

Amphotericin is superior to itraconazole as initial therapy for talaromycosis in terms of six-month mortality, clinical response, and fungicidal activity.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1056/NEJMoa1613306

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Tropical Medicine
Role:
Author


Wellcome Trust More from this funder
UK Department for International Development More from this funder
Medical Research Council More from this funder


Publisher:
Massachusetts Medical Society
Journal:
New England Journal of Medicine More from this journal
Volume:
376
Pages:
2329-2340
Publication date:
2017-06-01
Acceptance date:
2017-03-15
DOI:
EISSN:
1533-4406
ISSN:
0028-4793


Keywords:
Pubs id:
pubs:687680
UUID:
uuid:e4abb43e-545b-4769-91bf-41ba1116d3e7
Local pid:
pubs:687680
Source identifiers:
687680
Deposit date:
2017-03-31
ARK identifier:

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP